Suprax — Class III drug recall D-264-2013
Terminated recall by Lupin Pharmaceuticals Inc., reported 2013-04-24, distributed nationwide. Discoloration; Product may not meet specifications for color description once reconstituted.
| Recall number | D-264-2013 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2013-01-31 |
| Classified | 2013-04-18 |
| Reported by FDA | 2013-04-24 |
| Terminated | 2013-09-11 |
| Distributed | Nationwide (US) |
| Quantity | 64,368 bottles |
| NDC | 68180-0202-03 |
| Lot numbers | 2021A, 2024A, 2025A |
| Expiration dates | 2014-07-20 |
Product
Suprax (cefixime for oral suspension) USP, 100 mg/5 mL, 50 mL bottles (when reconstituted), Manufactured for Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Baltimore, MD 21202, Manufactured by Lupin Limited Mumbai 400 058 India, NDC 68180-202-03.
Reason for recall
Discoloration; Product may not meet specifications for color description once reconstituted.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-264-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.